In a trial of 8,322 patients, pelacarsen cut lipoprotein(a) by 78% but failed to reduce heart attacks, strokes or cardiovascular deaths over nearly five years.
Pelacarsen Cuts Lp(a) by 78% but Fails to Protect Heart
In a trial of 8,322 patients, pelacarsen cut lipoprotein(a) by 78% but failed to reduce heart attacks, strokes or cardiovascular deaths over nearly five years.